nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

28.10.2021 | COVID-19 | Letter to the Editor Zur Zeit gratis

Inflammatory biomarkers at hospital discharge are associated with readmission and death in patients hospitalized for COVID-19

verfasst von: Marleen A. Slim, Brent Appelman, Marcella C. A. Müller, Matthijs C. Brouwer, Alexander P. J. Vlaar, W. Joost Wiersinga, Lonneke A. van Vught, the Amsterdam UMC COVID-19 biobank study group

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Excerpt

Even though the survival of patients admitted with coronavirus disease 2019 (COVID-19) has increased with approximately 20% over the past year [1], readmission and mortality rates remain high (19.9% and 9.1%, respectively, within 2 months after hospital discharge (ward and intensive care unit (ICU)—admissions combined) [2]. In community-acquired pneumonia, elevated interleukin (IL)-6 and IL-10 at hospital discharge are associated with mortality in the subsequent 3 and 6 months, despite initial clinical recovery [3]. We aim to evaluate whether elevated levels of IL-6 and IL-10 at hospital discharge are associated with readmissions and mortality in the following 12 months in patients with COVID-19. …

Nur mit Berechtigung zugänglich

Prescott HC, Levy MM (2021) Survival from severe coronavirus disease 2019: is it changing? Crit Care Med 49(2):351–353. https://doi.org/10.1097/CCM.0000000000004753CrossRefPubMed

Donnelly JP, Wang XQ, Iwashyna TJ, Prescott HC (2020) Readmission and death after initial hospital discharge among patients with COVID-19 in a large multihospital system. JAMA 325(3):304–306. https://doi.org/10.1001/jama.2020.21465CrossRefPubMedCentral

Yende S, D’Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD et al (2008) Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 177(11):1242–1247. https://doi.org/10.1164/rccm.200712-1777OCCrossRefPubMedPubMedCentral

de Bruin S, Bos LD, van Roon MA, Tuip-de Boer AM, Schuurman AR, Koel-Simmelinck MJA et al (2021) Clinical features and prognostic factors in Covid-19: a prospective cohort study. EBioMedicine 67:103378. https://doi.org/10.1016/j.ebiom.2021.103378CrossRefPubMedPubMedCentral

Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL (2002) Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 162(11):1278–1284. https://doi.org/10.1001/archinte.162.11.1278CrossRefPubMed

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324(8):782–793. https://doi.org/10.1001/jama.2020.12839CrossRefPubMed

Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G et al (2021) The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 9(6):622–642. https://doi.org/10.1016/S2213-2600(21)00218-6CrossRefPubMedPubMedCentral

RECOVERY Collaborative Group (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397(10285):1637–1645. https://doi.org/10.1016/S0140-6736(21)00676-0CrossRef

Guideline Therapeutics and COVID-19: living guideline. World Health Organization. July 2021. https://apps.who.int/iris/bitstram/ahndle/10655/432368/WHO-2019-nCoV-therapeutics-2021.2-eng.pfd (accessed 17 Aug 2021)

Titel: Inflammatory biomarkers at hospital discharge are associated with readmission and death in patients hospitalized for COVID-19
verfasst von: Marleen A. Slim
Brent Appelman
Marcella C. A. Müller
Matthijs C. Brouwer
Alexander P. J. Vlaar
W. Joost Wiersinga
Lonneke A. van Vught
the Amsterdam UMC COVID-19 biobank study group
Publikationsdatum: 28.10.2021
Verlag: Springer Berlin Heidelberg
Schlagwort: COVID-19
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 12/2021
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-021-04355-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Inflammatory biomarkers at hospital discharge are associated with readmission and death in patients hospitalized for COVID-19

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2021

The prevalence and functional characteristics of CrpP-like in Pseudomonas aeruginosa isolates from China

Impact of 24/7 loading of blood culture bottles in a new automated incubator on the diagnosis of bloodstream infections

Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study

Development of a loop-mediated isothermal amplification assay for the rapid detection of six common respiratory viruses

Protective role of IL-18 in host defenses against group B Streptococcus

Comparative analysis of routine parasitological methods for recovery of cysts, molecular detection, and genotyping of Giardia duodenalis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin